WJPPS Citation

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • New Impact Factor
  • WJPPS Impact Factor has been Increased to 8.025 for Year 2024.

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • Scope Indexed
  • WJPPS is indexed in Scope Database based on the recommendation of the Content Selection Committee (CSC).

  • WJPPS: NOVEMBER ISSUE PUBLISHED
  • NOVEMBER 2024 Issue has been successfully launched on NOVEMBER 2024.

Abstract

EVALUATION OF SAFETY AND EFFICACY OF RUMAFLAM TABLETS & RUMAFLAM CREAM IN THE TREATMENT OF MUSCULOSKELETAL DISORDERS

Dr. K.H.H.V.S.S Narasimha Murthy and Dr.S.K.Mitra*

ABSTRACT

Musculoskeletal disorders occur due to excessive exertion and includes sprain, strain and damage to the body parts. This is one of the commonest reasons for reduced productivity at work due to sick leave and absenteeism. Therefore a need was felt to have a product that would help improve musculoskeletal disorders affecting bones, muscles, joints and cartilages. In the present clinical trial Rumaflam tablets and ointment, the two safe herbal products were found to be effective in the treatment of MSD. There were 20 males and 10 female patients in the trial and their age group varied between 35-68 years. They were asked to take Rumaflam tablets at the dose of 1 tablet twice daily and Rumaflam cream to be applied at the affected part twice daily for 8 weeks. There were 16 patients suffering from osteoarthritis, 3 patients had Arthritis of foot, 6 patients had low back pain, 5 patients had cervical spondylosis. At the end of the study 75% patients had complete relief, 24% patients had partial relief and only 1% patients did not respond well to the treatment. The product was found to be safe and no major side effect was reported during the trial.

Keywords: Musculoskeletal disorders, Pain, Osteoarthritis, Sprains, Swelling, joints, Spine, Spondylosis.


[Download Article]     [Download Certifiate]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More